Balefire LLC Raises Stake in Thermo Fisher Scientific Inc. $TMO

Balefire LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 90.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,355 shares of the medical research company’s stock after purchasing an additional 3,969 shares during the period. Thermo Fisher Scientific accounts for 0.8% of Balefire LLC’s investment portfolio, making the stock its 27th biggest holding. Balefire LLC’s holdings in Thermo Fisher Scientific were worth $4,052,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Thermo Fisher Scientific by 16.5% in the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 26,624 shares of the medical research company’s stock valued at $13,255,000 after acquiring an additional 3,768 shares in the last quarter. Venture Visionary Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.5% during the first quarter. Venture Visionary Partners LLC now owns 3,235 shares of the medical research company’s stock valued at $1,610,000 after buying an additional 139 shares during the period. Finally, Heritage Financial Services LLC lifted its position in Thermo Fisher Scientific by 24.3% during the 1st quarter. Heritage Financial Services LLC now owns 512 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 100 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TMO shares. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their target price for the company from $580.00 to $660.00 in a research note on Thursday, December 11th. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Finally, The Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $616.60.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 22,046 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total value of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares in the company, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.3%

Shares of NYSE TMO opened at $562.58 on Thursday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a market cap of $211.37 billion, a price-to-earnings ratio of 32.50, a price-to-earnings-growth ratio of 4.22 and a beta of 0.90. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company’s 50-day simple moving average is $567.63 and its 200-day simple moving average is $495.07.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific declared that its board has initiated a share buyback program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.